(Q40353264)

19 September 2017

Critical analysis of prostate-specific antigen doubling time calculation methodology (English)

1 reference

19 September 2017

Robert S Svatek

1

1 reference

19 September 2017

Michael Shulman

series ordinal

2

1 reference

19 September 2017

Pankaj K Choudhary

series ordinal

3

1 reference

19 September 2017

Elie Benaim

series ordinal

4

1 reference

19 September 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

19 September 2017

7

1 reference

inferred from page(s)

published in

Cancer

1 reference

19 September 2017

106

1 reference

19 September 2017

5

1 reference

19 September 2017

1047-1053

1 reference

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

19 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Statistical models for longitudinal biomarkers of disease onset.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

A note on a general definition of the coefficient of determination

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

The natural history of androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

The Long-Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21696

7 January 2021

Identifiers

DOI

10.1002/CNCR.21696

1 reference

19 September 2017

1 reference